ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2007
Corticosteroids for multiple sclerosis: I. Application for treating exacerbations.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02290444 (Effects of Adrenocorticotropic Hormone), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Adrenocorticotropic Hormone (ACTHAR Gel) on Recovery From Cognitive Relapses in Multiple Sclerosis
Who cites it
21 citing papers in PubMed, 63 citations in OpenAlex.
- Engineering controlled-release steroid therapeutics: fabrication and molecular design of self-assembled microparticles.Science advances · 2026Article
- A Defined Diet Combined with Sonicated Inoculum Provides a High Incidence, Moderate Severity Form of Experimental Autoimmune Encephalomyelitis (EAE).ACS pharmacology & translational science · 2024Article
- A Rare Case of Longitudinally Extensive Transverse Myelitis Following Febrile Illness: A Case Report.Cureus · 2024Article
- Cytoprotective E-WE thrombin reduces disease severity in a murine model of relapsing-remitting multiple sclerosis.American journal of physiology. Cell physiology · 2024Article
- The Diversity of Astrocyte Activation during Multiple Sclerosis: Potential Cellular Targets for Novel Disease Modifying Therapeutics.Healthcare (Basel, Switzerland) · 2023Review
- Plasma exchange in inflammatory demyelinating disorders of the central nervous system: reasonable use in the clinical practice.Arquivos de neuro-psiquiatria · 2023Review
- Review
- Article
- Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS).Neurology international · 2021Review
- Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.Neurology international · 2020Review
- Efficacy of Different Durations of Intravenous Methylprednisolone Treatment in Relapses of Multiple Sclerosis.Noro psikiyatri arsivi · 2017Article
- Uhthoff's phenomena in MS--clinical features and pathophysiology.Nature reviews. Neurology · 2013Review
- The effect of pulse methylprednisolone plus theophylline treatment on clinical, pulmonary and inflammatory markers in relapses of multiple sclerosis.Balkan medical journal · 2013Article
- Treatment of acute relapses in multiple sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013Review
- Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis.BMC medicine · 2012Review
- Current options for the treatment of optic neuritis.Clinical ophthalmology (Auckland, N.Z.) · 2012Article
- Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects.International immunopharmacology · 2011Article
- Symptomatic therapy in multiple sclerosis.Therapeutic advances in neurological disorders · 2011Article
- Management of acute exacerbations in multiple sclerosis.Annals of Indian Academy of Neurology · 2009Article
- Corticosteroids and plasma exchange in multiple sclerosis.Journal of neurology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is an inflammatory demyelinating disorder characterized by a multiphasic course of neurological exacerbations, periods of clinical remission, and, in most patients, ultimately progressive deterioration of functional capabilities. The relapsing-remitting phase of the disease involves acute interruption in neurological functioning relating to areas of inflammation in discrete central-tract systems. The treatment of MS exacerbations with anti-inflammatory agents such as corticosteroids and adrenocorticotropic hormone has represented an established practice throughout the neurology community. Although there is scientific rationale supporting application of these agents for this purpose, the broad diversity of approaches to using these drugs in clinical practice is a derivative of expert opinion and anecdotal experience. Ultimately, the treatment of MS-related exacerbations is part science, but mostly art. This review discusses the pharmacology of these agents, to better understand how they may act to mitigate attacks and to provide some practical formulations for how to use them in the clinic for the benefit of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.